Clinical Trials Browser

Phase 1/2 × INDUSTRY × Solutions × Clear all

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Phase 1/2 Active not recruiting

35 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT06022757 2024-02-23

KEYNOTE F19

Phase 1/2 Recruiting

204 enrolled

GenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Clinical Trials

MK-3475-D20

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

KEYNOTE F19